Veru Stock Surges 66% After Positive Breast Cancer Trial Results

Biopharmaceutical company Veru Inc (NASDAQ: VERU) shares are up over 65% on Monday after the company said its VERU-111 treatment has anti-cancer activity in Paclitaxel Sensitive and Paclitaxel Resistant Triple Negative Breast Cancer Tumors.

VERU-111 is an oral cytoskeleton disruptor that is currently being evaluated in both Phase 1b and Phase 2 clinical trials in men with prostate cancer. Veru said that in the prostate cancer clinical trials, the treatment has significant anti-tumour efficacy.

The company said that concerning breast cancer, “triple-negative breast cancer cells implanted into mice, orally administered VERU-111 almost completely inhibited tumour growth, whereas the placebo-treated tumours increased more than 10-fold.”

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

The company now plans to meet with the FDA in the first half of 2021 and advance VERU-111 into Phase 2b clinical trials in women with metastatic triple-negative breast cancer in 2021.  

After opening the session at $10.82 per share, Veru Inc’s stock is now at $10.57, up 66.48% on the day. 

PEOPLE WHO READ THIS ALSO VIEWED:

• Key stock market statistics for 2020
• Arvinas Stock Jumps 95% After Positive PROTAC Update
• Trade stocks with eToro